Established in 2006, the Vall d´Hebron Institute of Oncology (VHIO) is a leading comprehensive cancer center of excellence where its scientists and research physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer. Undertaking one of Spain´s most dynamic cancer research programs, VHIO is dedicated to delivering on the promise of precision medicine in oncology – turning cancer discovery into more effective treatments and better practice for the care of our patients.
Research at VHIO: translation toward precision oncology
Organized into four main programs: Preclinical, Translational, Clinical, and Core Technologies, VHIO´s team of some 300 researchers and physician scientists focus on understanding the fundamental biology of human cancer, from cellular and molecular biology and genetics through to therapeutics.
Its optimal organizational structure, coupled with its privileged location within the campus of the Vall d´Hebron University Hospital – affording direct access to patients as well as the entire spectrum of oncology professionals who care for them, allows VHIO to tackle the many unresolved questions in ultimately outsmarting the multifaceted, heterogeneous and complex disease that is cancer.
VHIO is governed by the following bodies: the Board of Trustees, the Board’s Executive Committee, the Scientific Director and the Managing Director. It also has a consultative body, the Scientific Committee.
The Governing Bodies ensure that VHIO’s vision is carried out in an effective way so that the Foundation complies with its mandate to promote and develop excellence in cancer research.